Business

Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

articleHinova Pharmaceuticals, Inc. Class ADecember 30, 20245/news/voluntary-disclosure-on-of-obtaining-fda-approval-for-clinical-trial-application-of-oral-protac-drug-hp568-tablets-in-the-treatment-of-erher2-advanced-breast-cancer
Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast Cancer

About this update from Hinova Pharmaceuticals, Inc. Class A

Voluntary Disclosure on of Obtaining FDA Approval for Clinical Trial Application of Oral PROTAC Drug HP568 Tablets in the Treatment of ER+/HER2- Advanced Breast CancerThe abstract is for reference only. Please refer to the full text of the announcement on the very day.Link of Full Text for Reference: View Attachment

View stock analysis, news, and events for Hinova Pharmaceuticals, Inc. Class A